Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
- Written by PR Newswire
![]() |
Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1] which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate
SYDNEY, Dec. 14, 2022 /PRNewswire/ -- Actinogen...